Trial Profile
An evaluation of the safety and tolerability of different doses of Recombinant Anti HER2 for injection (open study section) HL02 in Chinese healthy male subjects compared HL02 with Herceptin ? the pharmacokinetics, safety ,tolerability and immunogenicity, randomized, double-blind, Comparative study of pharmacokinetics clinica
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Aug 2017
Price :
$35
*
At a glance
- Drugs HL-02 (Primary) ; Trastuzumab
- Indications Breast cancer; Male breast cancer
- Focus Pharmacokinetics
- 21 Aug 2017 New trial record